Health and Youth Care Inspectorate – Pharmaceutical Products

CERTIFICATE NUMBER: NL/H 18/2003797

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Netherlands confirms the following:

The manufacturer: Annora Pharma Private Limited

Site address: Sy. No. 261, Annaram Village, Gummadidala Mandal, Sangareddy District, Telangana,

502313, India

DUNS Number: 65-098-0746

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 111(4) of Directive 2001/83/EC transposed in the following national legislation:

Art. 100 of the Medicines Act

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2018-03-15**, it is considered that it complies with:

• The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC³

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

Online EudraGMDP, Ref key: 48541 Issuance Date: 2018-06-15 Signatory: Confidential Page 1 of 2

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

 $^{^2}$ Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

1.2	Non-sterile products
102	1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.13 Tablets
1.5	Packaging
	1.5.1 Primary Packing
	1.5.1.13 Tablets
	1.5.2 Secondary packing
1.6	Quality control testing
	1.6.2 Microbiological: non-sterility
	1.6.3 Chemical/Physical

2018-06-15

Name and signature of the authorised person of the Competent Authority of Netherlands

Confidential

Health and Youth Care Inspectorate – Pharmaceutical

Affairs

Tel: *Confidential* Fax: *Confidential*